Byung Jo Park

Recommended Change in the N Descriptor Proposed by the International Association for the Study of Lung Cancer: A Validation Study

Byung Jo Park, Tae Ho Kim, Sumin Shin et al. · Journal of Thoracic Oncology · 2019 · 85 citations · Full text

Medicine, Oncology, Cancer Screening +3

FCN3 functions as a tumor suppressor of lung adenocarcinoma through induction of endoplasmic reticulum stress

Haeyeon Jang, Yukyung Jun, Suyeon Kim et al. · Cell Death and Disease · 2021 · 47 citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer

Jung Hee Lee, Hong Kwan Kim, Byung Jo Park et al. · Lung Cancer · 2017 · 29 citations

Medicine, Oncology, Surgery +17

Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)

Jii Bum Lee, Sujin Choi, Hyo Sup Shim et al. · Journal of Thoracic Oncology · 2024 · 19 citations · Full text

Medicine, Oncology, Pharmacology +16

Characterization of <i>TNNC1</i> as a Novel Tumor Suppressor of Lung Adenocarcinoma.

Suyeon Kim, Jae-Won Kim, Yeonjoo Jung et al. · PubMed · 2020 · 17 citations · Full text

Medicine, Molecular Biology, Oncology +16